Trial Profile
An Open-Label, One-Period Study in Patients Receiving Methadone or Buprenorphine/Naloxone Maintenance Therapy to Evaluate the Effect of SCH 503034 (Boceprevir) on Either Methadone or Buprenorphine/Naloxone Plasma Concentrations (Protocol No. P08123)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary) ; Buprenorphine/naloxone; Methadone
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 24 Jan 2012 Additional trial centre identified as reported by ClinicalTrials.gov.
- 17 Jan 2012 Actual patient number (3) added as reported by ClinicalTrials.gov.
- 17 Jan 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.